Serafin Zawadzki

Mr. Serafin Zawadzki


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SZSerafin Zawadzki
Serafin Zawadzki
ÁMÁngela Martín-Serrano
Ángela Martín-Serrano
EOElżbieta Okła
Elżbieta Okła
MKMarta Kędzierska
Marta Kędzierska
SGSandra Garcia-Gallego
Sandra Garcia-Gallego
KMKatarzyna Miłowska
Katarzyna Miłowska
Gene therapy presents an innovative approach to the treatment of previously incurable diseases. The advancement of research in the field of nanotechnology has the potential to overcome the current limitations and challenges of conventional therapy methods, and therefore to unlocking the full potential of dendrimers for use in the gene therapy of neurodegenerative disorders. The blood–brain barrier (BBB) poses a significant challenge when delivering therapeutic agents to the central nervous system. In this study, we investigated the biophysical properties of dendrimers and their complexes with siRNA directed against the apolipoprotein E (APOE) gene to identify an appropriate nanocarrier capable of safely delivering the cargo across the BBB. Our study yielded valuable insights into the complexation process, stability over time, the mechanisms of interaction, the influence of dendrimers on the oligonucleotide's spatial structure, and the potential cytotoxic effects on human cerebral microvascular endothelium cells. Based on our findings, we identified that the dendrimer G3Si PEG6000 was an optimal candidate for further research, potentially serving as a nanocarrier capable of safely delivering therapeutic agents across the BBB for the treatment of neurodegenerative disorders.

Verified
Journal Article
Open access
PDF file
KJKarolina Juszczak
Karolina Juszczak
AKAnna Kubicka
Anna Kubicka
RKRadoslaw Kitel
Radoslaw Kitel
GDGrzegorz Dzido
Grzegorz Dzido
MŁMagdalena Łabieniec-Watała
Magdalena Łabieniec-Watała
MTMateusz Dawid Tomczyk
Mateusz Dawid Tomczyk
Hexokinase 2 (HK2), an enzyme of the sugar kinase family, plays a dual role in glucose metabolism and mediating cancer cell apoptosis, making it an attractive target for cancer therapy. While positive HK2 expression usually promotes cancer cells survival, silencing or inhibiting this enzyme has been found to improve the effectiveness of anti-cancer drugs and even result in cancer cell death. Previously, benitrobenrazide (BNBZ) was characterized as a potent HK2 inhibitor with good anti-cancer activity in mice, but the effect of its trihydroxy moiety (pyrogallol-like) on inhibitory activity and some cellular functions has not been fully understood. Therefore, the main goal of this study was to obtain the parent BNBZ (2a) and its three dihydroxy derivatives 2b–2d and to conduct additional physicochemical and biological investigations. The research hypothesis assumed that the HK2 inhibitory activity of the tested compounds depends on the number and location of hydroxyl groups in their chemical structure. Among many studies, the binding affinity to HK2 was determined and two human liver cancer cell lines, HepG2 and HUH7, were used and exposed to chemicals at various times: 24 h, 48 h and 72 h. The study showed that the modifications to the structures of the new BNBZ derivatives led to significant changes in their activities. It was also found that these compounds tend to aggregate and exhibit toxic effects. They were found to contribute to: (a) DNA damage, (b) increased ROS production, and (c) disruption of cell cycle progression. It was observed that, HepG2, occurred much more sensitive to the tested chemicals than the HUH7 cells; However, regardless of the used cell line it seems that the increase in the expression of HK2 in cancer cells compared to normal cells which have HK2 at a very low level, is a serious obstacle in anti-cancer therapy and efforts to find the effective inhibitors of this enzyme should be intensified.

12 November 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SZSerafin Zawadzki
Serafin Zawadzki
EOElżbieta Okła
Elżbieta Okła
SMSylwia Michlewska
Sylwia Michlewska
TMTomasz Makowski
Tomasz Makowski
ABAdam Buczkowski
Adam Buczkowski
KMKatarzyna Milowska
Katarzyna Milowska
Upon intravenous administration, nanoparticles quickly become enveloped by plasma proteins, lipids, and sugars, forming a biomolecular corona that redefines their biological identity and directs systemic distribution. In this study, we examine a third-generation, positively charged, PEGylated carbosilane dendrimer engineered for the delivery of therapeutic siRNA across the blood-brain barrier. Employing a comprehensive array of analytical techniques—including fluorescence quenching assays, circular dichroism spectroscopy, isothermal titration calorimetry, atomic force microscopy, and transmission electron microscopy—we characterize the dendrimer’s binding kinetics and thermodynamics, and its impact on structure of human serum albumin, transferrin and complex environment of plasma. Our findings reveal that the dendrimer induces distinct conformational rearrangements at both tertiary and secondary levels, with thermodynamic analyses indicating that the interactions are predominantly driven by favorable entropy changes and multivalent binding. Furthermore, the dendrimer appears to promote a reorganization of plasma components, potentially leading to aggregation and misfolding reminiscent of fibril formation. Collectively, these findings provide critical insights into the more profound understanding of nanoparticle-protein interactions affecting the biodistribution and hemocompatibility of nanovectors and lay a foundation for further research aimed at safer and more effective therapeutic applications.

10 February 2026 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
SZSerafin Zawadzki
Serafin Zawadzki
SSSimon Suty
Simon Suty
EOElżbieta Okła
Elżbieta Okła
POPaula Ortega
Paula Ortega
FMFrancisco Javier De La Mata
Francisco Javier De La Mata
KMKatarzyna Milowska
Katarzyna Milowska
The development of nanocarriers offers a promising strategy for the delivery of therapeutics to the central nervous system. However, the clinical translation of nanosystems hinges on their interactions with blood components, which not only dictate their biodistribution and therapeutic efficacy but also may pose potential risks to hemostasis. In this study, we assess the hemocompatibility of a novel, third-generation PEGylated carbosilane dendrimer (G3Si PEG6000) and its dendriplex designed for siRNA delivery across the blood-brain barrier pertinent to Alzheimer's disease. Utilizing a comprehensive array of advanced analytical techniques, we assess cellular responses, cytokine expression, hemorheological properties, hematological parameters, and coagulation dynamics within a physiologically relevant environment. Our findings demonstrate that the investigated nanosystem elicits changes in blood rheology, immune recognition, and the intrinsic coagulation cascade, yet these effects remain below thresholds associated with clinically significant adverse outcomes. Hemolysis was ∼8-fold lower for dendriplexes than the dendrimer in PBS at the highest concentration (accordingly 3.5 ± 0.14% vs 27.46 ± 4.66%, 24 h), in 55% plasma, both formulations were nonhemolytic across all concentrations. Whole blood viscosity increased by up to ∼11% (dendrimer) and ∼16% (dendriplex) relative to the control. At 10 μM, the dendrimer approximately doubled the aPTT, whereas the corresponding dendriplex increased the aPTT by ∼30% of the control. Importantly, neither adverse effects on red blood cell and platelet indices nor toxicological responses in white blood cells were observed under the tested conditions. These findings not only support the translational potential of the studied nanosystem for therapy but also emphasize the critical role of the therapeutic cargo and the formation of a biomolecular corona in shaping the nanocarrier's biological identity and its subsequent interactions within the bloodstream. The results provide a compelling scientific basis for advancing this platform in further investigations.

29 August 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
EOElżbieta Okła
Elżbieta Okła
MHMarcin Hołota
Marcin Hołota
Sylwia MichlewskaSylwia Michlewska
Sylwia Michlewska
SZSerafin Zawadzki
Serafin Zawadzki
KMKatarzyna Milowska
Katarzyna Milowska
Maksim IonovMaksim Ionov
Maksim Ionov
Background: The proportion of people suffering from neurodegenerative conditions, such as Alzheimer’s disease (AD), is increasing in the population year on year. Despite the constant effort of researchers, these conditions remain incurable and can only be managed by alleviation or delaying of symptoms. The lack of suitable treatment is caused by constricted access to the brain, limited by the brain-blood barrier. The aim of this work was to investigate two pegylated gold nanoparticles as potential carriers of therapeutic siRNA and their impact on the cellular functions of Human Brain Endothelial Cells. Methods and Results: Nanoparticles AuNP14a and AuNP14b complexed with siRNA were internalized by HBEC-5i cells and located in the cytoplasm. The genotoxicity assay proved that the nucleus was not affected and complexed nanoparticles did not cause DNA damage. The reactive oxygen species formation and mitochondrial membrane potential changes were measured and showed an adaptive response of cells after compound administration. Results obtained in a cytotoxicity assay conducted on astrocytes and pericytes, which are components of the blood–brain barrier, confirmed the biosafety of tested nanoparticles. Conclusions: In summary, it was shown that AuNP14a and AuNP14b are promising candidates as nanocarriers for therapeutic nucleic acids through biological barriers.

22 July 2026 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
SZSerafin Zawadzki
Serafin Zawadzki
EOElżbieta Okła
Elżbieta Okła
POPaula Ortega
Paula Ortega
FMFrancisco Javier De La Mata
Francisco Javier De La Mata
Maksim IonovMaksim Ionov
Maksim Ionov
KMKatarzyna Milowska
Katarzyna Milowska
The tight regulation of bidirectional solute flux between the systemic circulation and neural tissue by the blood−brain barrier (BBB) remains a principal obstacle to effective pharmacotherapy of the central nervous system. In this study, we evaluate the biocompatibility and biodistribution of a novel third-generation PEGylated carbosilane dendrimer (G3Si PEG6000) and its siRNA dendriplex with an APOE4-directed siRNA relevant to late-onset Alzheimer’s disease using a tiered, upstream strategy that progresses from BBB-relevant monocultures to a capillary-weighted BBB model and in vivo/ex vivo biodistribution in mice, in accordance with current recommendations for nanomaterial testing. In endothelial cells, pericytes, and astrocytes, mitochondrial/redox profiling (MTT, DCF-ROS, and JC-1 ΔΨm) defined tolerated exposure ranges. Complexation with siRNA consistently attenuated apparent cytotoxicity across cell types, yet both free and complexed formulations elicited modest ROS and dose-dependent ΔΨm depolarization, indicating persistent mitochondrial stress. In the BBB model, responses were concentration- and formulation-dependent: 10 µM free dendrimers produced sustained impedance and nuclear confluence loss with sheet-like detachment, whereas the 0.1−2.5 µM free dendrimer and the dendriplex induced transient, recoverable perturbations or increases in impedance and proliferation. In vivo, whole-body IVIS imaging demonstrated prolonged systemic exposure for the dendriplex and an ex vivo kidney-dominant, liver-secondary distribution; no robust dendriplex signal was detected in brain fluorescence by planar NIR-I IVIS under the applied acquisition conditions. Collectively, these data indicate that siRNA complexation broadens the functional window at the BBB model with partially recoverable barrier effects and improved systemic exposure, while not substantially reducing mitochondrial or oxidative stress responses. The results provide a mechanistically informed basis for dose optimization and efficacy testing of this dendrimer−siRNA platform in CNS indications and for advancing this platform in further investigations targeting Alzheimer's disease.